CRESTONE – Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 monoclonal antibody for Advanced or Metastatic Solid Tumours (MoST CRESTONE in Australia)

November 16, 2021January 11, 2022

Posters & Oral Presentations

by Elevation Oncology

CRESTONE Clinical Trial

#10655 – Trials in Progress Virtual Poster Presentation

Presented at COSA 2021

Presenting Author: Dr Subotheni Thavaneswaran, Medical Oncologist at The Kinghorn Cancer Centre / Garvan Institute of Medical Research

Save this Presentation

Download PDF

Other Related Resources

October 16, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

September 29, 2020February 22, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

October 26, 2020March 1, 2021

Posters & Oral Presentations

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements Read More

January 15, 2021April 7, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) Read More

March 29, 2021April 8, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions Read More

April 10, 2021April 7, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions Read More